Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma

Science Translational Medicine

Volumn 4, Issue 127, 2012, Pages

  Munson, Jennifer M ^a   Fried, Levi ^b   Rowson, Sydney A ^a   Bonner, Michael Y ^b   Karumbaiah, Lohitash ^a   Diaz, Begoña ^c   Courtneidge, Sara A ^c   Knaus, Ulla G ^d   Brat, Daniel J ^b   Arbiser, Jack L ^b,e   Bellamkonda, Ravi V ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IMIPRAMINE BLUE; LIPOSOME; NANOCARRIER; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; DRUG CARRIER; IMIPRAMINE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; NANOENCAPSULATION; NANOPHARMACEUTICS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; SURVIVAL TIME; TOXICITY TESTING; ADJUVANT CHEMOTHERAPY; ANIMAL; BRAIN TUMOR; CANCER INVASION; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; GLIOMA; HUMAN; PATHOLOGY; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; IMIPRAMINE; LIPOSOMES; NANOPARTICLES; NEOPLASM INVASIVENESS; RATS; TREATMENT OUTCOME;

EID: 84859129495     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003016     Document Type: Article

References (47)

1. J. S. Barnholtz-Sloan, A. E. Sloan, A. G. Schwartz, Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J. Neurosurg. 99, 458-466 (2003).
2. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, R. O. Mirimanoff; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
3. R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. Taphoorn, R. C. Janzer, S. K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A. A. Brandes, J. Gijtenbeek, C. Marosi, C. J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R. O. Mirimanoff; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
4. A. Giese, R. Bjerkvig, M. E. Berens, M. Westphal, Cost of migration: Invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624-1636 (2003).
5. C. Wild-Bode, M. Weller, A. Rimner, J. Dichgans, W. Wick, Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma. Cancer Res. 61, 2744-2750 (2001).
6. F. Di Nicolantonio, S. J. Mercer, L. A. Knight, F. G. Gabriel, P. A. Whitehouse, S. Sharma, A. Fernando, S. Glaysher, S. Di Palma, P. Johnson, S. S. Somers, S. Toh, B. Higgins, A. Lamont, T. Gulliford, J. Hurren, C. Yiangou, I. A. Cree, Cancer cell adaptation to chemotherapy. BMC Cancer 5, 78 (2005).
7. K. Valerie, W. Hawkins, J. Farnsworth, R. Schmidt-Ullrich, P. S. Lin, C. Amir, J. Feden, Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther. 8, 3-8 (2001).
8. S. Brem, B. Tyler, K. Li, G. Pradilla, F. Legnani, J. Caplan, H. Brem, Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother. Pharmacol. 60, 643-650 (2007).
9. J. Sheehan, C. P. Cifarelli, K. Dassoulas, C. Olson, J. Rainey, S. Han, Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide. J. Neurosurg. 113, 234-239 (2010).
10. C. Di, A. K. Mattox, S. Harward, C. Adamson, Emerging therapeutic targets and agents for glioblastoma migrating cells. Anticancer Agents Med. Chem. 10, 543-555 (2010).
11. J. Dancey, E. A. Sausville, Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2, 296-313 (2003).
12. L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, E. A. Neuwelt, Chemotherapy delivery issues in central nervous system malignancy: A reality check. J. Clin. Oncol. 25, 2295-2305 (2007).
13. A. Agarwal, D. L. Jaye, C. M. Giegerman, R. V. Bellamkonda, Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. J. Biomed. Mater. Res. A 87, 728-738 (2008).
14. K. M. McNeeley, E. Karathanasis, A. V. Annapragada, R. V. Bellamkonda, Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30, 3986-3995 (2009).
15. D. D. Lasic, J. J. Vallner, P. K. Working, Sterically stabilized liposomes in cancer therapy and gene delivery. Curr. Opin. Mol. Ther. 1, 177-185 (1999).
16. K. Fabel, J. Dietrich, P. Hau, C. Wismeth, B. Winner, S. Przywara, A. Steinbrecher, W. Ullrich, U. Bogdahn, Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92, 1936-1942 (2001).
17. P. Hau, K. Fabel, U. Baumgart, P. Rümmele, O. Grauer, A. Bock, C. Dietmaier, W. Dietmaier, J. Dietrich, C. Dudel, F. Hübner, T. Jauch, E. Drechsel, I. Kleiter, C. Wismeth, A. Zellner, A. Brawanski, A. Steinbrecher, J. Marienhagen, U. Bogdahn, Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100, 1199-1207 (2004).
18. B. Diaz, G. Shani, I. Pass, D. Anderson, M. Quintavalle, S. A. Courtneidge, Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci. Signal. 2, ra53 (2009).
19. J. L. Arbiser, J. Petros, R. Klafter, B. Govindajaran, E. R. McLaughlin, L. F. Brown, C. Cohen, M. Moses, S. Kilroy, R. S. Arnold, J. D. Lambeth, Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 99, 715-720 (2002).
20. L. Fried, J. L. Arbiser, The reactive oxygen-driven tumor: Relevance to melanoma. Pigment Cell Melanoma Res. 21, 117-122 (2008).
21. K. Greish, Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 624, 25-37 (2010).
22. H. L. Fillmore, J. Shurm, P. Furqueron, S. S. Prabhu, G. T. Gillies, W. C. Broaddus, An in vivo rat model for visualizing glioma tumor cell invasion using stable persistent expression of the green fluorescent protein. Cancer Lett. 141, 9-19 (1999).
23. N. M. Marina, D. Cochrane, E. Harney, K. Zomorodi, S. Blaney, N. Winick, M. Bernstein, M. P. Link, Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study. Clin. Cancer Res. 8, 413-418 (2002).
24. E. T. Dams, P. Laverman, W. J. Oyen, G. Storm, G. L. Scherphof, J. W. van Der Meer, F. H. Corstens, O. C. Boerman, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292, 1071-1079 (2000).
25. T. Sugahara, Y. Korogi, S. Tomiguchi, Y. Shigematsu, I. Ikushima, T. Kira, L. Liang, Y. Ushio, M. Takahashi, Posttherapeutic intraaxial brain tumor: The value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am. J. Neuroradiol. 21, 901-909 (2000).
26. J. K. Park, T. Hodges, L. Arko, M. Shen, D. Dello Iacono, A. McNabb, N. Olsen Bailey, T. N. Kreisl, F. M. Iwamoto, J. Sul, S. Auh, G. E. Park, H. A. Fine, P. M. Black, Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28, 3838-3843 (2010).
27. F. Lefranc, J. Brotchi, R. Kiss, Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23, 2411-2422 (2005).
28. F. Lefranc, S. James, I. Camby, J. F. Gaussin, F. Darro, J. Brotchi, J. Gabius, R. Kiss, Combined cimetidine and temozolomide, compared with temozolomide alone: Significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J. Neurosurg. 102, 706-714 (2005).
29. V. Mégalizzi, V. Mathieu, T. Mijatovic, P. Gailly, O. Debeir, N. De Neve, M. Van Damme, G. Bontempi, B. Haibe-Kains, C. Decaestecker, Y. Kondo, R. Kiss, F. Lefranc, 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9, 358-369 (2007).
30. W. C. Broaddus, Y. Liu, L. L. Steele, G. T. Gillies, P. S. Lin, W. G. Loudon, K. Valerie, R. K. Schmidt-Ullrich, H. L. Fillmore, Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J. Neurosurg. 91, 997-1004 (1999).
31. K. Watanabe, K. Sato, W. Biernat, O. Tachibana, K. von Ammon, N. Ogata, Y. Yonekawa, P. Kleihues, H. Ohgaki, Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3, 523-530 (1997).
32. P. K. Singal, N. Iliskovic, Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905 (1998).
33. T. C. Chen,W. Wang, E. B. Golden, S. Thomas, W. Sivakumar, F. M. Hofman, S. G. Louie, A. H. Schönthal, Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett. 302, 100-108 (2011).
34. X. Dolcet, D. Llobet, J. Pallares, X. Matias-Guiu, NF-kB in development and progression of human cancer. Virchows Arch. 446, 475-482 (2005).
35. X. Yuan, J. Curtin, Y. Xiong, G. Liu, S. Waschsmann-Hogiu, D. L. Farkas, K. L. Black, J. S. Yu, Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392-9400 (2004).
36. E. Kaczarek, S. Zapf, H. Bouterfa, J. C. Tonn, M. Westphal, A. Giese, Dissecting glioma invasion: Interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int. J. Dev. Neurosci. 17, 625-641 (1999).
37. N. Tapon, A. Hall, Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol. 9, 86-92 (1997).
38. M. A. Forget, R. R. Desrosiers, M. Del, R. Moumdjian, D. Shedid, F. Berthelet, R. Béliveau, The expression of rho proteins decreases with human brain tumor progression: Potential tumor markers. Clin. Exp. Metastasis 19, 9-15 (2002).
39. C. Albiges-Rizo, O. Destaing, B. Fourcade, E. Planus, M. R. Block, Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J. Cell Sci. 122, 3037-3049 (2009).
40. D. Gianni, N. Taulet, C. DerMardirossian, G. M. Bokoch, c-Src-mediated phosphorylation of NoxA1 and Tks4 induces the reactive oxygen species (ROS)-dependent formation of functional invadopodia in human colon cancer cells. Mol. Biol. Cell 21, 4287-4298 (2010).
41. J. de Groot, V. Milano, Improving the prognosis for patients with glioblastoma: The rationale for targeting Src. J. Neurooncol. 95, 151-163 (2009).
42. T. Shono, N. Yokoyama, T. Uesaka, J. Kuroda, R. Takeya, T. Yamasaki, T. Amano, M. Mizoguchi, S. O. Suzuki, H. Niiro, K. Miyamoto, K. Akashi, T. Iwaki, H. Sumimoto, T. Sasaki, Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int. J. Cancer 123, 787-792 (2008).
43. A. Conti, M. Ageunnouz, D. La Torre, S. Cardali, F. F. Angileri, C. Buemi, C. Tomasello, D. G. Iacopino, D. D'Avella, G. Vita, F. Tomasello, Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation of the nuclear factor-κB antiapoptotic activity in human gliomas. J. Neurosurg. 103, 873-881 (2005).
44. G. D. Ford, B. D. Ford, E. C. Steele Jr., A. Gates, D. Hood, M. A. Matthews, S. Mirza, P. R. Macleish, Analysis of transcriptional profiles and functional clustering of global cerebellar gene expression in PCD3J mice. Biochem. Biophys. Res. Commun. 377, 556-561 (2008).
45. K. von Löhneysen, D. Noack, M. R. Wood, J. S. Friedman, U. G. Knaus, Structural insights into Nox4 and Nox2: Motifs involved in function and cellular localization. Mol. Cell. Biol. 30, 961-975 (2010).
46. H. E. Fierz-David, L. Blangey, Fundamental Process of Dye Chemistry (Interscience Publishers, New York, 1979), pp. 298-308.
47. T. P. Robinson, R. B. Hubbard IV, T. J. Ehlers, J. L. Arbiser, D. J. Goldsmith, J. P. Bowen, Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorg. Med. Chem. 13, 4007-4013 (2005).